METHUSELAH ARCHIVE INGREDIENTS / INTRAVENOUS IMMUNOGLOBULIN (IVIG)

Intravenous immunoglobulin (IVIG)

human tissue
provenance:human tissue
first introduced:2024
regulatory status:off label
context:Intravenous immunoglobulin (IVIG) is a pooled-donor-derived immunoglobulin preparation that has been used clinically since the 1980s for autoimmune neurological and hematologic indications (Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, immune thrombocytopenia, primary immunodeficiencies). The use of IVIG in the aging-rejuvenation context dates from the Circulate Health protocol and the *Aging Cell* trial published in May 2025; the biweekly TPE+IVIG arm showed the largest biological-age reduction in the trial (-2.61 years vs. -1.32 years for monthly TPE alone).
MECHANISM CLAIMED
IVIG provides pooled donor-derived antibodies and immunomodulatory factors that, in combination with TPE-mediated removal of aged recipient plasma, produce coordinated rejuvenation of immune and inflammatory aging markers via the documented immunomodulatory mechanisms of IVIG in autoimmune indications.
MECHANISM ACTUAL
IVIG has documented immunomodulatory effects in autoimmune indications, including Fc-receptor blockade, complement modulation, and anti-idiotypic antibody activity. Its mechanism in the aging-rejuvenation context is proposed rather than demonstrated. The differential effect of biweekly TPE+IVIG versus monthly TPE alone in the *Aging Cell* trial is the only published evidence base for the addition of IVIG to TPE for aging-related use; independent replication is not yet published. The trial reports surrogate-endpoint effects only, with no hard-endpoint data.
INTERVENTIONS USING IT
NOTES

Intravenous immunoglobulin is the pooled-donor-derived antibody and immunomodulator preparation that, in the Circulate protocol, is infused following therapeutic plasma exchange. IVIG itself is an established clinical product with decades of safety experience in autoimmune neurological and hematologic indications; the novel element is its use for aging-related off-label purposes in combination with TPE. The biological role attributed to IVIG in the aging context (immunomodulation, immune-system rejuvenation, complement and Fc-receptor effects translated from the autoimmune-indication mechanism) is proposed and consistent with IVIG’s known pharmacology, but is not yet supported by trial evidence beyond the single Aging Cell publication, which carries a disclosed conflict of interest (the investigators are members of the commercializing company Circulate, Inc.; the paper states it received no specific funding).